EARA on Mythryl: “#Drug doubles life expectancy of pancreatic cancer patients 💊 The…”

#Drug doubles life expectancy of pancreatic cancer patients 💊 The #FDA approved #daraxonrasib, from Revolution Medicines, after patients in a #Phase3 clinical trial lived twice as long as those on #chemotherapy. The drug was studied in #mice and #monkeys before #HumanTrials. 🔗 shorturl.at/BHYZd

shorturl.atEARA | News - Drug doubles life expectancy of pancreatic cancer patientsThe US Food and Drug Administration (FDA) has approved a drug for advanced pancreatic cancer following a phase 3 clinical trial in which patients lived twice as long as those who were treated…

16/9/26, 8:00 am0 reposts0 likes

Post